All In Biotech

Drug Trial Radar · NCT07923383

An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates

An Open-label, Single-sequence Drug-drug Interaction Study to Investigate the Effects of Duvakitug on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Nov 3, 2026

Primary completion

Aug 8, 2028

Study completion Aug 29, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Teva Branded Pharmaceutical Products R&D LLC
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single group, 2-period, Phase 1, single-arm study. The primary purpose of this study is to investigate the effects of duvakitug on the pharmacokinetics of selected cytochrome P450 substrates in adult participants with moderately to severely active ulcerative colitis or Crohn's disease. Approximately 25 participants will be enrolled. The total study duration per participant will be approximately 166 days.

Conditions

  • Ulcerative Colitis
  • Crohn's Disease

Interventions

  • DuvakitugDrug

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC for CYP isoform specific substrates midazolam, omeprazole, warfarin, caffeine, and metoprololTime frame: At Treatment Period 1 (CYP substrates alone, Day 1) and after 12 weeks of duvakitug (Treatment Period 2, Day 85)
  2. AUClast for CYP isoform specific substrates midazolam, omeprazole, warfarin, caffeine, and metoprololTime frame: At Treatment Period 1 (CYP substrates alone, Day 1) and after 12 weeks of duvakitug (Treatment Period 2, Day 85)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.